Cohorting based on nasal methicillin-resistant Staphylococcus aureus status: an opportunity to share more than a room

Am J Infect Control. 2013 May;41(5):401-4. doi: 10.1016/j.ajic.2012.10.015. Epub 2013 Mar 15.

Abstract

Background: Hospital roommates are cohorted with similarly colonized patients to decrease methicillin-resistant Staphylococcus aureus (MRSA) transmission risk. However, little is known about differences in S aureus nasal and extranasal carriage between hospital roommates who are in MRSA or non-MRSA designated rooms.

Methods: Patients sharing hospital rooms were cultured for S aureus in the nose, throat, and other body sites. Differences in S aureus methicillin and mupirocin susceptibility and USA300 type were evaluated.

Results: Eighty-two patients comprising 48 roommate pairs were studied. Among 6 roommate pairs in MRSA rooms, 3 (50%) had differences in carriage based on having methicillin-susceptible S aureus at an extranasal body site. In non-MRSA rooms, 19 (45%) roommate pairs had differences in S aureus carriage. Extranasal colonization was significantly associated with discordance between roommates, P < .001. Antibiotic exposure, ward type, and the duration of room sharing were not associated with discordance.

Conclusion: Patients have almost a 50% chance of having differences in S aureus colonization compared with their hospital roommate, even in MRSA-designated rooms. Cohorting by MRSA status at the time of admission may not be as effective a control strategy as horizontal measures that do not rely on known colonization with S aureus or other pathogens.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Asymptomatic Infections*
  • Cross Infection / drug therapy
  • Hospitalization
  • Hospitals
  • Humans
  • Methicillin-Resistant Staphylococcus aureus / classification
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification*
  • Mupirocin / therapeutic use
  • Nasal Cavity / microbiology*
  • Patients' Rooms*
  • Risk Factors
  • Staphylococcal Infections / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Mupirocin